Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

By sjmartinez • January 7, 2025

Blauvelt A, Kircik L, Schlesinger T, Pierce E, Burge R, Behling M, Atwater AR, ElMaraghy H, Armstrong A. Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis. J Dermatolog Treat. 2025 Dec;36(1):2442720. doi: 10.1080/09546634.2024.2442720. Epub 2025 Jan 6. PMID: 39761965.

Tags: atopic dermatitis, Dermatology, Eczema Area and Severity Index, lebrikizumab, Publications, Quality of Life

Multi-cytokine based TWAS for seven inflammatory skin disorders identify candidate causal genes in keratinocytes

Zhang H, Patrick MT, Sarkar MK, Bogle R, Li Q, Uppala R, Perez White BE, Petukhova L, Dand N, Stuart PE, Christiano AM, Simpson MA,[...]

Increased risk of spontaneous abortion risk with alopecia areata independent of antiphospholipid syndrome and endometritis

Podolsky AS, Singal A, Goh C, Lipner SR. Increased risk of spontaneous abortion risk with alopecia areata independent of antiphospholipid syndrome and endometritis. J Am[...]

New insights into Rett syndrome pathogenesis: defining the role of MEPC2 in DNA damage

Mansooralavi N, Lowry WE. New insights into Rett syndrome pathogenesis: defining the role of MEPC2 in DNA damage. Front Neurol. 2026 May 11;17:1711771. doi: 10.3389/fneur.2026.1711771.[...]